|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cancer Genome Atlas Research Network:
Comprehensive molecular profiling of lung adenocarcinoma. Nature.
511:543–550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jänne PA and Johnson BE: Effect of
epidermal growth factor receptor tyrosine kinase domain mutations
on the outcome of patients with non-small cell lung cancer treated
with epidermal growth factor receptor tyrosine kinase inhibitors.
Clin Cancer Res. 12:4416s–4420s. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhou C and Yao LD: Strategies to improve
outcomes of patients with Egrf-Mutant non-small cell lung cancer:
Review of the literature. J Thorac Oncol. 11:174–186. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mitsudomi T and Yatabe Y: Mutations of the
epidermal growth factor receptor gene and related genes as
determinants of epidermal growth factor receptor tyrosine kinase
inhibitors sensitivity in lung cancer. Cancer Sci. 98:1817–1824.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shepherd FA, Rodrigues Pereira J, Ciuleanu
T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S,
Smylie M, Martins R, et al: Erlotinib in previously treated
non-small-cell lung cancer. N Engl J Med. 353:123–132. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Morgillo F, Della Corte CM, Fasano M and
Ciardiello F: Mechanisms of resistance to EGFR-targeted drugs: Lung
cancer. ESMO Open. 1:e0000602016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kobayashi S, Ji H, Yuza Y, Meyerson M,
Wong KK, Tenen DG and Halmos B: An alternative inhibitor overcomes
resistance caused by a mutation of the epidermal growth factor
receptor. Cancer Res. 65:7096–7101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Engelman JA, Zejnullahu K, Mitsudomi T,
Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen
J, et al: MET amplification leads to gefitinib resistance in lung
cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Terai H, Soejima K, Yasuda H, Nakayama S,
Hamamoto J, Arai D, Ishioka K, Ohgino K, Ikemura S, Sato T, et al:
Activation of the FGF2-FGFR1 autocrine pathway: A novel mechanism
of acquired resistance to gefitinib in NSCLC. Mol Cancer Res.
11:759–767. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nukaga S, Yasuda H, Tsuchihara K, Hamamoto
J, Masuzawa K, Kawada I, Naoki K, Matsumoto S, Mimaki S, Ikemura S,
et al: Amplification of EGFR wild type alleles in non-small cell
lung cancer cells confers acquired resistance to mutation-selective
EGFR tyrosine kinase inhibitors. Cancer Res. 15:2078–2089. 2017.
View Article : Google Scholar
|
|
13
|
Kobayashi S, Boggon TJ, Dayaram T, Jänne
PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos
B: EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pao W, Miller VA, Politi KA, Riely GJ,
Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of
lung adenocarcinomas to gefitinib or erlotinib is associated with a
second mutation in the EGFR kinase domain. PLoS Med. 2:e732005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bean J, Brennan C, Shih JY, Riely G, Viale
A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, et al: MET
amplification occurs with or without T790M mutations in EGFR mutant
lung tumors with acquired resistance to gefitinib or erlotinib.
Proc Natl Acad Sci USA. 104:20932–20937. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nakachi I, Naoki K, Soejima K, Kawada I,
Watanabe H, Yasuda H, Nakayama S, Yoda S, Satomi R, Ikemura S, et
al: The combination of multiple receptor tyrosine kinase inhibitor
and mammalian target of rapamycin inhibitor overcomes erlotinib
resistance in lung cancer cell lines through c-Met inhibition. Mol
Cancer Res. 8:1142–1151. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yano S, Wang W, Li Q, Matsumoto K,
Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka
Y, et al: Hepatocyte growth factor induces gefitinib resistance of
lung adenocarcinoma with epidermal growth factor
receptor-activating mutations. Cancer Res. 68:9479–9487. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Thomson S, Petti F, Sujka-Kwok I, Epstein
D and Haley JD: Kinase switching in mesenchymal-like non-small cell
lung cancer lines contributes to EGFR inhibitor resistance through
pathway redundancy. Clin Exp Metastasis. 25:843–854. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sequist LV, Waltman BA, Dias-Santagata D,
Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger
S, Cosper AK, et al: Genotypic and histological evolution of lung
cancers acquiring resistance to EGFR inhibitors. Sci Transl Med.
3:75ra262011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gentzler RD and Johnson ML: Complex
decisions for first-line and maintenance treatment of advanced
wild-type non-small cell lung cancer. Oncologist. 20:299–306. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Butts CA, Ding K, Seymour L,
Twumasi-Ankrah P, Graham B, Gandara D, Johnson DH, Kesler KA, Green
M, Vincent M, et al: Randomized phase III trial of vinorelbine plus
cisplatin compared with observation in completely resected stage IB
and II non-small-cell lung cancer: Updated survival analysis of
JBR-10. J Clin Oncol. 28:29–34. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Scagliotti GV, Parikh P, von Pawel J,
Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U,
Digumarti R, Zukin M, et al: Phase III study comparing cisplatin
plus gemcitabine with cisplatin plus pemetrexed in
chemotherapy-naive patients with advanced-stage non-small-cell lung
cancer. J Clin Oncol. 26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Socinski MA, Bondarenko I, Karaseva NA,
Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P,
Zhang H, et al: Weekly nab-paclitaxel in combination with
carboplatin versus solvent-based paclitaxel plus carboplatin as
first-line therapy in patients with advanced non-small-cell lung
cancer: Final results of a phase III trial. J Clin Oncol.
30:2055–2062. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Langer CJ: The emerging world role of
irinotecan in lung cancer. Oncology (Williston Park). 15:(7 Suppl
8). S15–S21. 2001.
|
|
25
|
Fossella FV: Docetaxel in second-line
treatment of non-small-cell lung cancer. Clin Lung Cancer. 3:(Suppl
2). S23–S28. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fletcher JI, Haber M, Henderson MJ and
Norris MD: ABC transporters in cancer: More than just drug efflux
pumps. Nat Rev Cancer. 10:147–156. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Arao T, Fukumoto H, Takeda M, Tamura T,
Saijo N and Nishio K: Small in-frame deletion in the epidermal
growth factor receptor as a target for ZD6474. Cancer Res.
64:9101–9104. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yasuda H, Park E, Yun CH, Sng NJ,
Lucena-Araujo AR, Yeo WL, Huberman MS, Cohen DW, Nakayama S,
Ishioka K, et al: Structural, biochemical, and clinical
characterization of epidermal growth factor receptor (EGFR) exon 20
insertion mutations in lung cancer. Sci Transl Med. 5:216ra1772013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Busacca S, Sheaff M, Arthur K, Gray SG,
O'Byrne KJ, Richard DJ, Soltermann A, Opitz I, Pass H, Harkin DP,
et al: BRCA1 is an essential mediator of vinorelbine-induced
apoptosis in mesothelioma. J Pathol. 227:200–208. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cheung-Ong K, Giaever G and Nislow C:
DNA-damaging agents in cancer chemotherapy: Serendipity and
chemical biology. Chem Biol. 20:648–659. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Haimeur A, Conseil G, Deeley RG and Cole
SP: The MRP-related and BCRP/ABCG2 multidrug resistance proteins:
Biology, substrate specificity and regulation. Curr Drug Metab.
5:21–53. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bessho Y, Oguri T, Ozasa H, Uemura T,
Sakamoto H, Miyazaki M, Maeno K, Sato S and Ueda R: ABCC10/MRP7 is
associated with vinorelbine resistance in non-small cell lung
cancer. Oncol Rep. 21:263–268. 2009.PubMed/NCBI
|
|
34
|
Oguri T, Achiwa H, Sato S, Bessho Y,
Takano Y, Miyazaki M, Muramatsu H, Maeda H, Niimi T and Ueda R: The
determinants of sensitivity and acquired resistance to gemcitabine
differ in non-small cell lung cancer: A role of ABCC5 in
gemcitabine sensitivity. Mol Cancer Ther. 5:1800–1806. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gan PP, Pasquier E and Kavallaris M: Class
III beta-tubulin mediates sensitivity to chemotherapeutic drugs in
non small cell lung cancer. Cancer Res. 67:9356–9363. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Stuckler D, Singhal J, Singhal SS, Yadav
S, Awasthi YC and Awasthi S: RLIP76 transports vinorelbine and
mediates drug resistance in non-small cell lung cancer. Cancer Res.
65:991–998. 2005.PubMed/NCBI
|
|
37
|
Mackey JR, Mani RS, Selner M, Mowles D,
Young JD, Belt JA, Crawford CR and Cass CE: Functional nucleoside
transporters are required for gemcitabine influx and manifestation
of toxicity in cancer cell lines. Cancer Res. 58:4349–4357.
1998.PubMed/NCBI
|
|
38
|
Goan YG, Zhou B, Hu E, Mi S and Yen Y:
Overexpression of ribonucleotide reductase as a mechanism of
resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell
line. Cancer Res. 59:4204–4207. 1999.PubMed/NCBI
|
